Metrics as of 10/17/2026, 08:48 AM (Berlin time), refresh in progress.
Whitehawk Therapeutics Stock
Whitehawk Therapeutics Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David J. Lennon
- Employees
- 32
- Market cap
- $165 M
- IPO
- 01/08/2017
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its…
Whitehawk Therapeutics stock: price history
1D
-4.9%
1W
-17.9%
1M
-28.5%
6M
-29.7%
YTD
+19.4%
1Y
+10.7%
2Y
+35.0%
5Y
-89.4%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~25% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Whitehawk Therapeutics
Analyst assessment of Whitehawk Therapeutics
PRICE TARGET LOW
US$7.00
CONSENSUS
US$8.33
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
No current analyst ratings available.
Whitehawk Therapeutics stock metrics
P/E
-2.58
P/B
1.31
EV/EBITDA
-0.98
RETURN ON EQUITY
-9.1%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
41.5%
FLOAT SHARES
23,677,553
AVG. DAILY VOLUME (30D)
361,215
Insider transactions (SEC)
Dalal Anupam
Castelein Caley
Giacobello Scott M.
BALL BRYAN
Dugan Margaret
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Whitehawk Therapeutics stock
What does Whitehawk Therapeutics do?
Whitehawk Therapeutics Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David J. Lennon, the company employs around 32 people.
The IPO was on 01/08/2017; the stock trades on NASDAQ under the ticker WHWK.
What do analysts say about Whitehawk Therapeutics stock?
The average price target is US$8.33, ranging from US$7.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does Whitehawk Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -25% stronger than usual.
Does Whitehawk Therapeutics pay a dividend?
No, Whitehawk Therapeutics currently does not pay a dividend.
Which stocks are comparable to Whitehawk Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Whitehawk Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Whitehawk Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.